Glancy Binkow & Goldberg LLP reminds investors of Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) (NASDAQ:ICPT) that all purchasers of Intercept securities between January 9, 2014 and January 10, 2014, inclusive (the “Class Period”), have until April 22, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

Intercept is a development stage biopharmaceutical company, focused on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing Intercept’s proprietary bile acid chemistry. The Company’s primary drug compound, obeticholic acid (“OCA”), is in various stages of clinical development for the treatment of cirrhosis and other chronic liver diseases. The complaint filed in the United States District Court for the Southern District of New York alleges that the Company’s January 9, 2014, and January 10, 2014, announcements concerning the Phase 2 clinical trial of OCA for treatment of non-alcoholic steatohepatitis failed to disclose material information.

On January 10, 2014, the National Institutes of Health’s National Institute of Diabetes and Digestive Kidney Diseases issued a statement that although the efficacy primary endpoint for OCA had already been met, study participants suffered disproportionate levels of lipid abnormalities. Following this news, Intercept stock dropped from its $445.83 per share closing price on January 10, 2014, to a closing price of $255.12 per share on January 14, 2014.

If you are a member of the Class described above, you may move the Court no later than April 22, 2014, to serve as lead plaintiff; however, you must meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to shareholders@glancylaw.com, or visit our website at http://www.glancylaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.